Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venmax Drugs & PharmaceuticalsBOM:531015 +1.88%33 Gross Margin % is 7.81% as of Mar. 2026, which is 4% above its 10-year median of 7.53. GuruFocus rates BOM:531015 with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 942 Drug Manufacturers companies, Venmax Drugs & Pharmaceuticals ranks worse than 95.86% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Venmax Drugs & Pharmaceuticals had a gross margin of 7.81% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Venmax Drugs & Pharmaceuticals Gross Margin % Related Terms
Venmax Drugs & Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Venmax Drugs & Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venmax Drugs & Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venmax Drugs & Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Venmax Drugs & Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Venmax Drugs & Pharmaceuticals (BOM:531015) has a Gross Margin % of 7.81% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Venmax Drugs & Pharmaceuticals and its competitors. This is near median its historical median of 7.53. According to the industry distribution chart, Venmax Drugs & Pharmaceuticals ranks #903 out of 942 companies in the Drug Manufacturers industry, placing it in the top 95.9%.
Is Venmax Drugs & Pharmaceuticals' Gross Margin % too high?
Venmax Drugs & Pharmaceuticals' current Gross Margin % of 7.81% is near median its 10-year median of 7.53. The Drug Manufacturers industry median Gross Margin % is 48.54. Venmax Drugs & Pharmaceuticals' value of 7.81% is 83.9% below this industry median. Based on the distribution chart, Venmax Drugs & Pharmaceuticals ranks #903 out of 942 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Venmax Drugs & Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Venmax Drugs & Pharmaceuticals' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Venmax Drugs & Pharmaceuticals ranks #903 out of 942 companies for Gross Margin %. This places Venmax Drugs & Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.54. Venmax Drugs & Pharmaceuticals' value of 7.81% is 83.9% below this benchmark. While the company's 10-year median is 7.53 vs. the industry median of 48.54, Venmax Drugs & Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venmax Drugs & Pharmaceuticals's current Gross Margin % of 7.81% is 83.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Venmax Drugs & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venmax Drugs & Pharmaceuticals's current Gross Margin % is 7.81%, which is near median its own 10-year median of 7.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venmax Drugs & Pharmaceuticals stock overvalued right now?
Venmax Drugs & Pharmaceuticals (BOM:531015) has a current Gross Margin % of 7.81%. The current Gross Margin % is 7.81%, which is near median its 10-year median of 7.53 and 83.9% below the Drug Manufacturers industry median of 48.54. Venmax Drugs & Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Venmax Drugs & Pharmaceuticals (BOM:531015), the current Gross Margin % is 7.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Venmax Drugs & Pharmaceuticals Business Description
Venmax Drugs & Pharmaceuticals Ltd is engaged in the manufacturing and sale of bulk drugs. The company is engaged in the business of IT & ITES services.
33GF Score
Get the complete analysis for BOM:531015
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531015 has been successfully added to your 
